Didn't someone mention support at $25?
Well, time for it to kick in, right?
But don't keep your breath - sorry longs.
We're on our way to $12 1/2.
Whether you like it or not.
The next five years are likely to be better
For this year revenues WILL increase sharply. WITH
ZERO DOUBT. Contracts have already been signed that
haven't contributed to 1998 ! And I guarantee (if that
means anything to you :-} ) that more deal expansions
and/or near partners will follow in 1999 and 2000. etc.
If you want a drug to treat/cure Alzheimer's etc.
it's a HUGE help knowing alot about the gene
responsible for it. There are so many diseases, conditions
that will have what seems now to be miraculous
One good question you raised was why haven't INCY's
partners have anything in development ? As a practical
matter the pharmas don't have to release every detail
about all the drugs they have in development. So they
don't. A small biotech company whose life depends on one
or two drugs HAS to realease every detail to keep
investors from....panicking ?
This argument is
interesting....the long side arguments are too long-term oriented to
be relevant to the shorts, and the short side
arguments are too short-term oriented to be relavant to the
This is a clash of time-horizon
So these tight bollingers are giving you that
warm feeling, eh? I guessed it! Incy is ready to fly!
Oh yes! Seriously, I agree!
Incy is ready to
But gee, something must be wrong, because why
does it stay GROUNDED when it's been ready to fly FOR
Regarding long-term performance, oh
yes, that's my favorite subject. Is that the 1yr
return of INCY you are referring to?
Or perhaps the
three year return vs. the Nasdaq?
tdeank. You may have lost a bundle, but you can still
sell your INCY.
I have no idea what 'the people at the top' have
to say about this matter. Or what they HAD to say.
Presumably the enormous, vast, gold-plated future of this
wonderful industry has not changed all that much over the
last 12 months.
But do I feel as if I were missing
You seem not to realize that this
stock has been, simply put, CRASHING through the floor
during that year, taking all those listening,
intelligent, knowledgable longs with them. Including you, I
So there. Go figure what it's worth to know all
about your awesome genetics landscape.
you should indicate how much knowledge of biology is
required to invest in INCY. Hopefully that'll shake out a
bunch of nitwits holding INCY here.
phrased it ;-), is that INCY is severly oversold.
Check out the stoastics and the bollinger bands are
tightening up this is ready to fly silly boy.
term potential of this one is beyond your intellect
however I do see the comic relief in your posts as a
plus, however I doubt your over 10 or 11 years
Good luck with your attempt to gain some attention I'm
done talking to you untill your present some
legitimate data pro or con.
I suggest that you go to
your local medical school and check out a couple of
books on genetics, cell biology, and pharmacology. If
can understand the concepts, you will find that the
knowledge aquired by companys such as Incyte will be the
root of medical care in the coming century. The
expansion of the life sciences will make the information
age look trivial.
Your posts which highlight
the risk inherent in these types of companies is
pertinent. Nobody here is not aware of these risks. As those
in 'the know' recognize, the genetic landscape is
vast, complicated, potentially awesome but largely
Have the revenues from companies such as
Incyte been realized? Of course not. Have revenues from
Internet companies been realized? Of course not. Do both
offer potentially exciting technologies. YES! The only
difference is that anyone can access Yahoo to find a missing
friend and only a few have the appropriate training to
acknowledge and understand the genetic revolution. I suggest
you consider what the people at the top have to say
on this matter before you maintain your short
position on this stock. You may well be right, or you may
well be wrong, but I would not play in this sector
without at least a little understanding of biology.
There have been ZERO clinical trials announced by
Incyte's partners relating to drugs based on Incyte's
genomic information (except if you count diaDexus, the
diagnostics partnership between SmithKline Beecham and INCY).
Human Genome Sciences, on the other hand, has announced
3 trials based on its discoveries. HGSI, however,
has to report its trials since they are material to
its earnings. Pfizer, B-Meyers, Johnson and Johnson,
etc. don't have to talk about Phase 1 trials since
these events have negligible impact on near term
earnings. In fact, for competitive reasons they generally
don't want to discuss these trials. But again you're
right there is no evidence that trials on Incyte based
candidates have taken place.
Surely it's not
inconceivable that since HGSI has 3 genomic drugs in trials
that a few of Incyte's 26 partners might have 1 or 2
drugs in trials, too.
Final thoughts...Why have
Pfizer, J&J and every single other subscriber who's
subscription period has run out renew their subscriptions (and
in many cases EXPAND)? Why do these companies
continue to renew? Don't they know that the information is
useless? Don't they know about the public databases?